![(3Z)-N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methy…](https://static.cymitquimica.com/cas-image/395397-3z-n-3-chlorophenyl-3-35-dimethyl-4-4-methylpiperazin-1-yl-carbonyl-1h-pyrrol-2-yl-methylidene-n-methyl-2-oxo-23-dihydro-1h-indole-5-sulfonamide.png)
CAS: 658084-23-2 - (3Z)-N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylidene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
Formula:C28H30ClN5O4S
InChI:InChI=1/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16-
- Sinonimi:
- Su11274
- Su 11274
| Marchio | Dati del prodotto | Purezza | Fascia di prezzo | Consegna prevista |
|---|---|---|---|---|
 | SU 11274 REF: 7W-GL1480CAS: 658084-23-2 | - - - | Prezzo su richiesta | Mar 10 Dic 24 |
 | SU 11274 REF: 3D-FS65178CAS: 658084-23-2 | Min. 95% | 299,00 €~833,00 € | Mar 17 Dic 24 |
 | SU11274 REF: TM-T6154CAS: 658084-23-2 | 98.62% - 99.44% | 46,00 €~673,00 € | Ven 10 Gen 25 |
Ref: 7W-GL1480
| Dimensione non definita | Prezzo su richiesta |
Consegna stimata in Stati Uniti, il Martedì 10 Dicembre 2024
SU 11274
CAS:658084-23-2
MET tyrosine kinase inhibitor; anti-proliferative; pro-apoptotic
Formula:
C28H30ClN5O4S
Purezza:
Min. 95%
Colore e forma:
Yellow To Orange Solid
Peso molecolare:
568.09 g/mol
Ref: 3D-FS65178
| 10mg | 299,00 € | ||
| 50mg | 833,00 € |
Consegna stimata in Stati Uniti, il Martedì 17 Dicembre 2024
SU11274
CAS:658084-23-2
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects …
Formula:
C28H30ClN5O4S
Purezza:
98.62% - 99.44%
Colore e forma:
Orange Powder
Peso molecolare:
568.09
Ref: TM-T6154
| 1mg | 46,00 € | ||
| 2mg | 58,00 € | ||
| 5mg | 95,00 € | ||
| 10mg | 147,00 € | ||
| 25mg | 276,00 € | ||
| 50mg | 455,00 € | ||
| 100mg | 673,00 € | ||
| 1mL*10mM (DMSO) | 150,00 € |
Consegna stimata in Stati Uniti, il Venerdì 10 Gennaio 2025
